The purpose of this study is to evaluate the use of linear accelerator (LINAC)-based stereotactic body radiotherapy (SBRT) boost with multileaf collimator technique after pelvic radiotherapy (RT) in patients with endometrial cancer.
Postoperative radiotherapy (RT) is used to improve local control in the management of endometrial cancer [1] and RT-related side effects should be reduced as much as possible resulting from the expected long-term survival in these patients [2] .
SBRT is a treatment technique which delivers higher ablative doses of radiation to the target tissue while minimizing surrounding normal tissue exposure under image guidance. SBRT boost may be used in the management of patients with endometrial cancer with the dose and fractionation schemes identical to High Dose Rate-Brachytherapy (HDR-BT). The advantages of SBRT over brachytherapy include improved sparing of normal tissues with optimal three-dimensional coverage, dose escalation without increasing radiationinduced toxicity, and improved target dose distributions to smaller pelvic target volumes with high-precision immobilization and reduced set-up uncertainties. Moreover, anesthesia or sedation is not required for SBRT applications [3] . This emerging technology may be implemented by either CyberKnife Robotic Radiosurgery System or LINAC-based radiosurgery which need precise image guidance due to the large ablative radiation doses delivered in a limited number of fractions.
In this study, we evaluated the use of image guided LINACbased SBRT boost with multileaf collimator technique after pelvic external RT in patients with endometrial cancer.
Patients and methods
Consecutive patients with endometrial cancer referred to our department for RT between April 2010 and May 2011 were evaluated. All 18 patients had endometrial cancer and had undergone surgery (total abdominal hysterectomy and bilateral salpingo-oophorectomy with pelvic / paraortic nodal sampling) before RT. All patients were treated with postoperative pelvic RT using a dose of 45 Gy in 25 fractions.
After pelvic RT was completed, all patients were treated with SBRT boost to the vaginal cuff. Total SBRT boost dose was 18 Gy delivered in 3 fractions at 1-week intervals. Median age was 62 (53-65) years. Histopathological diagnosis was endometrial adenocarcinoma in all 18 patients. Out of the total 18 patients, 10 patients (55.6 %) had stage IB, 6 patients (33.3 %) had stage II, and 2 patients (11.1 %) had stage IIIC1 endometrial cancer according to American Joint Committee on Cancer (AJCC 2010) staging. Patient and tumor characteristics are summarized in Table 1 .
All patients initially received pelvic external RT to clinical target volume 1 ( CTV1: pelvic lymph nodes, tumor bed) with a 4-field box technique in the supine position. All fields were treated daily, 5 days a week, with 6-18 MV X-rays.
The SBRT boost treatment to CTV2 (vaginal cuff) was delivered using dynamic-arc techniques with a commercially available multileaf collimator-based LINAC treatment machine (Elekta Synergy, UK). Arc Modulation Optimization Algorithm (AMOA) was used to optimize treatment planning with 6-MV X-rays.
For SBRT boost treatment planning, the rectum was emptied the night before and 1 to 2 hours before simulation using sodium phosphate enemas. No special preparation was mandatory to reproduce bladder filling during treatment. All patients were positioned in supine position with arms on the chest. Customized vacuum body (BlueBAG, Bodyfix system, Medizintechnik GmbH, Germany) was used for immobilization of the patient on treatment table with two-pin localization. Vaginal radio-opaque device (HDR-BT cylinder - Figure 1 ) was used as a reference for SBRT application to visualize the vaginal cuff CTV as the upper two thirds of the vagina at CT simulation (CT Lightspeed, GE Healthcare, Chalfont St. Giles, UK). According to the American Brachytherapy Society (ABS) recommendations, the largest diameter of cylinder that can be accommodated was used for simulation and treatment [4] .
After fixation of Bodyfix localizer (Medizintechnik GmbH, Germany) to CT Simulator, cross-sectional images with 1.25 mm slice thickness were acquired. In simulation for SBRT boost planning, 274 miliampers (mA), 400 width, and 50 length were used as CT acquisition parameters. The acquired images from CT Simulator were sent to the contouring workstation via network for SBRT planning. Advantage SimMD simulation and localization software (Advantage SimMD, GE, UK) was used to contour the CTV and organs-at-risk (OARs). Pretreatment MRI of patients were used to evaluate disease extent but not for treatment planning purposes since the main tool for SBRT planning was CT images acquired with vaginal cylinder. CTV2 was contoured as the upper two thirds of vagina (approximately 4 cm). Surrounding critical structures including the bladder, rectum, small bowel and femoral heads were contoured as OARs in planning CT images according to ICRU 38 recommendations [5] . 3D expansion of the CTV2 by 5 mm isotropically generated the PTV, which is consistent with the literature [6, 7] .
All contouring procedures were performed by an experienced radiation oncologist of gynecologic oncology. All 18 patients were treated with the dynamic-arc technique using a single isocenter and 9-17 arcs. Total prescribed SBRT dose was 18 Gy at a distance of 0.5 cm from the cylinder surface and was delivered in 3 fractions of 6 Gy at 1-week intervals. ERGO treatment planning system (ERGO + +, Elekta, UK) and dynamic conformal arc technique along with AMOA was used in SBRT treatment planning ( Figure 2 ). Dose volume histograms and isodose curves were individually generated for each patient ( Figure 3 ). Dose to the PTV, 1  IB  61  T1bN0M0  3  100  2  IIIC1  57  TIbN1M0  3  100  3  IB  53  T1bN0M0  3  100  4  II  62  T2N0M0  2  100  5  IB  65  T1bN0M0  3  100  6  IB  53  T1bN0M0  3  100  7  II  59  T2N0M0  3  100  8  IB  64  T1bN0M0  3  100  9  II  65  T2N0M0  2  100  10  IB  56  T1bN0M0  3  100  11  II  64  T2N0M0  2  90  12  IB  64  T2N0M0  3  90  13  IB  61  T1bN0M0  3  100  14  II  57  TIbN1M0  3  100  15  IB  53  T1bN0M0  3  100  16  IIIC1  64  T3bN1M0  2  90  17  IB  65  T1bN0M0  3  100  18  II  64  T2N0M0  2 OARs were recorded. Cone beam CT and XVI (X-ray Volume Imaging, Elekta, UK) were used for set-up verification. After treatment completion, local control assessment was done with pelvic MRI and gynecological examination at 3-month intervals for the first year and at 6-month intervals for the second year. Gastrointestinal and genitourinary toxicity was assessed using the CTCAE v 3. Informed consent was provided for each patient in the study along with ethics committee approval from Gulhane Military Medical Academy institutional review board.
Results
Between April 2010 and May 2011, 18 patients with stage I-III endometrial cancer were treated using LINAC-based SBRT boost after pelvic RT. The prescribed SBRT boost dose was 18 Gy in 3 fractions. In SBRT planning, mean PTV volume was 37.4 (31.8-52.7) cc. Mean dose to the PTV was 1915 (1742-2047) cGy. PTV coverage with the 90 % isodose line was achieved in all patients. Mean dose to the rectum was 569 cGy (273-1008 cGy) whereas mean dose to the bladder was 535 cGy (157-775 cGy) ( Table 2) .
At a median follow-up of 24 (8-26) months, local control rate was 100 %. All patients completed the prescribed radiotherapy.
No ≥ grade 3 acute toxicity requiring treatment interruption was encountered. The most common acute toxicities included diarrhea, nausea and urinary urgency/frequency. Acute grade 1 gastrointestinal toxicity (diarrhea and nausea) was observed in 8 patients (44.4 %). Grade 2 acute rectal toxicity (abdominal pain) was observed in 4 patients (22.2 %) whereas grade 2 late rectal toxicity was observed in 2 patients (11.1 %) (abdominal pain). Grade 1 acute sexual toxicity (dyspareunia and vaginal dryness) was observed in 6 patients (33.3 %) and grade 1 late sexual toxicity (dyspareunia and vaginal dryness) was observed in 4 patients (22.2 %). Grade 1 acute urinary toxicity (urgency/ frequency) was observed in 7 patients (38.8 %) and grade 2 acute urinary toxicity (urgency/frequency) was observed in 4 patients (22.2 %) whereas no urinary late toxicity was observed in all patients. Toxicity outcomes are shown on Table 3 .
Discussion
Quality of life has gained utmost priority for operable endometrial cancer patients with substantially improved life expectancy provided by multimodality treatment. Recent years have also witnessed dramatic development in cancer imaging and Image Guided Radiotherapy (IGRT) technology. Reducing acute and long-term treatment-related side effects through decreasing normal tissue radiation exposure during RT is a major challange in current gynecologic oncology practice [8] .
Brachytherapy has several potential limitations in compromising treatment outcomes. Since homogeneous dose distribution can not be thoroughly achieved with brachytherapy, vaginal surface mucosa may be exposed to higher doses than the deeper mucosa. Clinical implementation of brachytherapy requires a dedicated brachytherapy unit, and periodic exchange of expensive sources compared to LINAC-based SBRT. Moreover, while utilizing HDR-BT, it is quite difficult to deliver lower doses than the prescription dose to the OARs particularly in the setting of irregularly shaped tumors or in recurrent tumors which often extend deep into the vaginal mucosa. When delivering the vaginal cuff boost by brachytherapy, dose is prescribed to a depth of 0.5 cm. Since the 90 % isodose line is ovoidal, brachytherapy boost may not cover the non-ovoidal shaped tumor targets. The target may fall outside the 90 % isodose curve particularly in the craniocaudal axis in non-ovoidal shaped settings, resulting in profoundly compromised local control [9] .
SBRT is a hypofractionated treatment technology providing ablative radiation doses to eradicate small targets. It improves critical organ sparing and provides better target dose distribution with dose escalation opportunity in gynecologic oncology applications. Using this sophisticated technology with the dose and fractionation schemes identical to HDR-BT, Image-guided dynamic-arc SBRT boost treatment after external pelvic RT may be safely implemented without increasing normal tissue complications and accurate set-up verification [3] .
Stereotactic radiation may be delivered by a number of different devices. Brand name stereotactic treatment machines/systems include: Elekta Axesse, Elekta Synergy, CyberKnife, Truebeam, RapidArc, Novalis, TomoTherapy, Trilogy etc.
LINAC is one of several technologies that may be used for stereotactic body radiotherapy. There are no clearcut indications where one delivery system is preferred over the other. There are some technical advantages/disadvantages between the various systems, however, there has been no significant clinical advantage demonstrated between the various devices i.e., LINAC or CyberKnife in homogeneous groups of patients. What is clinically significant is that the appropriate case be chosen for SBRT and that the optimal radiation dose/volume and fractionation of treatments is provided which will be determined by the Radiation Oncologist.
Macchia et al. [6] used vaginal cylinder as SBRT reference for patients in the postoperative setting of endometrial cancer. Doses of 25 Gy and 30 Gy were delivered within 5 consecutive daily fractions to the upper two thirds of vagina. In their study, treatment with SBRT was tolerated well with the most common toxicity being grade 2 gastrointestinal toxicity.
In the study by Beatriz et al. [10] , vaginal cuff SBRT was used as an alternative to HDR-BT boost in gynecological tumor patients. Five gynecological cancer patients were treated with external pelvic postoperative irradiation. Pelvic intensity modulated radiation therapy (IMRT) was followed by vaginal cuff SBRT using RapidArc and the referential vaginal cylinder in all patients. The total dose delivered ranged from 9 Gy to 21 Gy given in 3 fractions. No patients developed acute toxicity in their small 5-patient group whereas late moderate toxicity of vaginal mucosal discharge and temporary urinary irritation was observed in 3 patients out of 5. They concluded that vaginal cuff SBRT was comparable to HDR-BT boost therapy.
Molla et al. [9] reported fractionated SBRT to be an excellent alternative to brachytherapy with target volume being defined at 3 cm proximal to the vaginal apex and at a depth of 5 mm from the vaginal surface. In their study including 16 patients, SBRT doses of 7 Gy x 2 fractions and 4 Gy x 5 fractions were delivered and well-tolerated without causing grade 3 toxicity.
In the study by Bicquart et al. [11] , local control and acute toxicity was assessed in patients with gynecological malignancies. Out of the total 14 patients, 4 patients were treated with definitive SBRT instead of a conventional brachytherapy boost. The average prescribed SBRT boost dose was 22.7 Gy delivered in 4-5 fractions. At a median follow-up of 7.6 months, they noted encouraging preliminary local control outcomes with minimal toxicity.
In the study by Jorcano et al. [12] , 26 patients with gynecological tumors treated with SBRT boost technique as an alternative to HDR-BT boost were evaluated for treatment outcomes. Pelvic external RT was followed by a final SBRT boost of 2 x 7 Gy to the vaginal vault. No severe (> grade 3) acute urinary or low-gastrointestinal (GI) toxicity was observed. In their study, they reported promising preliminary results on feasibility, tolerance, and outcome with SBRT and concluded that SBRT may be considered as an alternative to HDR-BT boost in gynecologic tumors.
We used CT-compatible vaginal cylindrical brachytherapy applicator as a reference for the vaginal cuff SBRT boost treatment and delivered the prescribed dose to the 4 cm of upper two-thirds of vagina defining the apex and to a depth of 5 mm Around the cylinder covering the PTV of 90 % isodose line in all patients achieving a homogeneous target dose distribution.
In our study, all patients were assessed with pelvic MRI and gynecological examination at 3-month intervals for the first year and at 6-month intervals for the second year. At median followup of 24 (8-26) months, local control rate was 100 %.
In our study, the most common acute toxicity observed was grade 1 diarrhea and nausea in 44.4 % of all 18 SBRT-boost patients. These acute side effects resolved till the first followup (12 weeks after treatment completion) in all but 2 patients. In these 2 patients, the side effects were noted to be resolved spontaneously at the sixth month follow-up visit. No ≥ grade 3 acute or late side effects were observed during the course of follow-up.
In the present study using PTV margins of 5 mm around the CTV, we found that SBRT boost to the vaginal cuff is a feasible and well-tolerated gynecological boost therapy modality, however small number of patients of our SBRT group and short follow-up time are the limitations of our study. In our study, we primarily aimed to assess local control and toxicity in patients with endometrial cancer treated with SBRT boost as an alternative to HDR-BT boost and noted excellent local control with acceptable and well-tolerated toxicity outcomes at a median follow-up of 24 months. In the light of the results of our study, consideration of SBRT for the vaginal cuff may improve normal tissue sparing and may decrease treatment related toxicity along with allowance to higher doses to be delivered to the target volume in the practice of definitive endometrial cancer radiotherapy.
In conclusion, with a limited number of gynecologic cancer patients and relatively short follow-up in our study, LINACbased SBRT boost to the vaginal cuff provided excellent local control with minimal toxicity. This sophisticated emerging technology is an effective modality which may replace Traditional brachytherapy boost despite the need for further studies including more patients with longer follow-up.
